Clinical trials: HBP
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00326092
- Testing
- Brinzolamide/Timolol
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Intracranial Hypertension
Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients
The purpose of this study is to prospectively evaluate the accuracy and safety of non-invasive intracranial pressure (ICP) measurements using the HeadSense-1000 (HS-1000) device compared to the current invasive external…
- Trial name
- NCT02695264
- Testing
- HS-1000 recording
- Where
- United States
- Sponsor
- HeadSense Medical
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Glaucoma
GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma
The purpose of this study is to evaluate the safety and efficacy of the GTS400 trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing…
- Trial name
- NCT01052558
- Testing
- iStent Inject (GTS400), Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 164 people
- Sponsor
- Glaukos Corporation
Glaucoma
IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
Uncontrolled glaucoma patients being treated with a prostaglandin agent alone or in combination with adjunctive drugs in fixed or unfixed combinations, will be switched from their current therapy to travoprost/timolol fixed…
- Trial name
- NCT00382226
- Testing
- Azopt
- Where
- Australia
- Volunteers
- 195 people
- Sponsor
- Alcon Research
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Elevated Intraocular Pressure (IOP)
Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure
This is a pilot, open-label, multi-center clinical study. Each potential subject that has met all screening inclusion/exclusion criteria will undergo a six-week washout phase where they will discontinue the use of their topical…
- Trial name
- NCT04962009
- Testing
- Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mati Therapeutics Inc.
Hypertension
Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment
This is a retrospective data analysis of patients with high blood pressure (hypertension) who took metoprolol for a minimum of 6 months who then switched to taking nebivolol for a minimum of 6 month to treat hypertension.
- Trial name
- NCT01758263
- Testing
- Metoprolol, Nebivolol
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Forest Laboratories
Open Angle Glaucoma
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
- Trial name
- NCT06246136
- Testing
- ELIOS, Competitor Device
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 194 people
- Sponsor
- Elios Vision, Inc.
Glaucoma, Ocular Hypertension
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate Ophthalmic Solution, 0.5% in the treatment of subjects…
- Trial name
- NCT02312544
- Testing
- OTX-TP, Timolol
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma Treatment Using Focused Ultrasound
UCP Glaucoma Treatment for Primary Glaucoma in China
To collect safety and efficacy data on Ultrasound Cycle Plasty treatment (UCP) in primary glaucoma asian patients.
- Trial name
- NCT04145830
- Testing
- Ultrasound Cyclo Plasty (UCP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Hypertension
To Demonstrate the Relative Bioavailability of Atenolol Tablets
To demonstrate the relative bioavailability of Atenolol tablets.
- Trial name
- NCT00913965
- Testing
- Atenolol Tablets 100 mg (Cord Laboratories), Atenolol Tablets 100 mg (Stuart Pharmaceutical)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
- Trial name
- NCT00846365
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Where
- 80 sites in United States, Chile and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Takeda
Glaucoma, Retinal Disease
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Trial name
- OCT (NCT03505567)
- Testing
- KOWA OCT Bi-µ, Optovue iVue 100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Hypertension
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696436
- Testing
- Azilsartan medoxomil, Valsartan, Olmesartan
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,291 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.